Last reviewed · How we verify

Metformin IR — Competitive Intelligence Brief

Metformin IR (Metformin IR) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Biguanide. Area: Diabetes.

marketed Biguanide AMP-activated protein kinase (AMPK) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Metformin IR (Metformin IR) — AstraZeneca. Metformin reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues, lowering blood glucose levels in type 2 diabetes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Metformin IR TARGET Metformin IR AstraZeneca marketed Biguanide AMP-activated protein kinase (AMPK)
Metformin discontinue Metformin discontinue University of Texas Southwestern Medical Center marketed Biguanide AMP-activated protein kinase (AMPK); hepatic glucose production
metformin\pioglitazone\exenatide metformin\pioglitazone\exenatide The University of Texas Health Science Center at San Antonio marketed Combination antidiabetic agent (biguanide + thiazolidinedione + GLP-1 receptor agonist) Multiple: AMPK pathway (metformin), PPAR-γ (pioglitazone), GLP-1 receptor (exenatide)
or Metformin HCl alone or Metformin HCl alone Bristol-Myers Squibb marketed Biguanide AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase
metformin+ gliclazide metformin+ gliclazide GlaxoSmithKline marketed Antidiabetic combination (biguanide + sulfonylurea) Metformin: mitochondrial glycerophosphate dehydrogenase; Gliclazide: ATP-sensitive potassium channels on pancreatic beta cells
Glimepiride/metformin fixed combination Glimepiride/metformin fixed combination Handok Inc. marketed Sulfonylurea/biguanide combination ATP-sensitive potassium channel (glimepiride); mitochondrial complex I / AMPK pathway (metformin)
metformin or sulfonylurea metformin or sulfonylurea Dr. Milan Gupta marketed Antidiabetic agents (biguanide and sulfonylurea) Metformin: AMP-activated protein kinase (AMPK) pathway; Sulfonylureas: ATP-sensitive potassium channel (KATP)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Biguanide class)

  1. AstraZeneca · 4 drugs in this class
  2. Merck Sharp & Dohme LLC · 3 drugs in this class
  3. University of Texas Southwestern Medical Center · 2 drugs in this class
  4. Mount Sinai Hospital, Canada · 2 drugs in this class
  5. GlaxoSmithKline · 2 drugs in this class
  6. Eli Lilly and Company · 2 drugs in this class
  7. University Magna Graecia · 2 drugs in this class
  8. First Affiliated Hospital of Wenzhou Medical University · 1 drug in this class
  9. Ente Ospedaliero Ospedali Galliera · 1 drug in this class
  10. Daewoong Pharmaceutical Co. LTD. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Metformin IR — Competitive Intelligence Brief. https://druglandscape.com/ci/metformin-ir. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: